Edwards Lifesciences VP plans 2027 retirement
Edwards Lifesciences Corporation (EW) reported that its Corporate Vice President, Strategy and Corporate Development, Donald E. Bobo, Jr., has notified the company of his decision to retire by mid-year 2027.
Rhea-AI Filing Summary
Edwards Lifesciences Corporation (EW) reported that its Corporate Vice President, Strategy and Corporate Development, Donald E. Bobo, Jr., has notified the company of his decision to retire by mid-year 2027. The board will begin a selection process promptly to identify a successor, with a transition of duties expected during 2027.
The company also states that Mr. Bobo is expected to remain with Edwards as a consultant through the end of 2027, providing continuity during and after the leadership transition.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Planned retirement timing: mid-year 2027
Consultancy period end: end of 2027
Form 8-K date: August 25, 2026
+1 more
4 metrics
Planned retirement timing
mid-year 2027
Timing of retirement of Corporate Vice President, Strategy and Corporate Development
Consultancy period end
end of 2027
Expected end of Donald E. Bobo, Jr.’s consultancy with the company
Form 8-K date
August 25, 2026
Date of the reported event under the Exchange Act
Signature date
August 28, 2026
Date the report was signed by the Chief Financial Officer
Key Terms
Form 8-K, Section 13 or 15(d) of the Securities Exchange Act of 1934, emerging growth company, Section 12(b) of the Act
4 terms
Form 8-K regulatory
"FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
Section 13 or 15(d) of the Securities Exchange Act of 1934 regulatory
"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"
emerging growth company regulatory
"405) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 12(b) of the Act regulatory
"Securities registered pursuant to Section 12(b) of the Act"
FAQ
What executive leadership change did Edwards Lifesciences (EW) disclose in this Form 8-K?
Edwards Lifesciences disclosed that Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, has decided to retire by mid-year 2027. The company plans to identify a successor and transition his duties during 2027, with Mr. Bobo remaining as a consultant through year-end 2027.
When will Donald E. Bobo, Jr. retire from Edwards Lifesciences (EW)?
Donald E. Bobo, Jr. has informed Edwards Lifesciences that he plans to retire by mid-year 2027. The company expects a transition of his duties during 2027 as part of the succession process.
Will Donald E. Bobo, Jr. remain involved with Edwards Lifesciences (EW) after retirement?
Yes. Edwards Lifesciences reports that Donald E. Bobo, Jr. is expected to remain as a consultant through the end of 2027, supporting the company following his retirement and during the leadership transition.
What role is affected by the announced retirement at Edwards Lifesciences (EW)?
The affected role is Corporate Vice President, Strategy and Corporate Development. Donald E. Bobo, Jr., who holds this position, has notified Edwards Lifesciences of his decision to retire by mid-year 2027.
How will Edwards Lifesciences (EW) handle succession for Donald E. Bobo, Jr.’s role?
Edwards Lifesciences states that a selection process will begin promptly to identify a successor to Donald E. Bobo, Jr. The company expects this process to result in a transition of duties during 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
